Stem cells in your nose? Rhinocyte says go for it at Stem Cells USA

Attendees of Stem Cells USA listened to Theresa Leezer from Rhinocyte, discussed the use of autologous olfactory epithelial cells for the treatment of neurodegenerative diseases. The first clinical trial will be for the treatment of spinal cord injury, which was awarded an orphan drug designation. Other planned uses of this platform technology include the treatment of Parkinson’s Disease, ALS, and possibly Type 1 Diabetes.

-Original content provided by an on-site blogger at the Stem Cells USA & Regenerative Medicine Congress